Immunovant (IMVT) Other Non-Current Assets (2024 - 2026)

Immunovant's Other Non-Current Assets history runs 3 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 0.81% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 0.81% YoY) and the FY2026 annual result came in at $7.7 million, up 0.81% from the prior year.
• Other Non-Current Assets was $7.7 million for Q1 2026 at Immunovant, down from $8.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $8.9 million in Q2 2025 and bottomed at $7.6 million in Q4 2024.
• A 3-year average of $8.2 million and a median of $7.7 million in 2026 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2025 — Other Non-Current Assets rose 17.13% — and 2026, when it climbed 0.81%.
• Immunovant's Other Non-Current Assets stood at $7.6 million in 2024, then gained by 17.13% to $8.9 million in 2025, then fell by 13.92% to $7.7 million in 2026.
• Business Quant data shows IMVT's Other Non-Current Assets at $7.7 million in Q1 2026, $8.9 million in Q4 2025, and $8.8 million in Q3 2025.